Claims for Patent: 7,022,475

Summary for Patent: 7,022,475

Title:	Genotyping assay to predict CYP3A5 phenotype
Abstract:	Genetic polymorphisms responsible or associated with altered expression of cytochrome P450 CYP3A5 enzyme are described. Single nucleotide polymorphisms are provided. Methods for identifying subjects having a low or high drug metabolizing phenotype associated with CYP3A5 expression are provided. Assays, kits and methods for determining and assaying the CYP3A5 genotype and phenotype of individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods for determining and evaluating an individual\'s metabolism of drugs and therapeutic agents, the potential for drug interactions, and thereby toxicity and effectiveness of certain drugs and treatment modalities, are provided.
Inventor(s):	Schuetz; Erin (Memphis, TN), Zhang; Jiong (Memphis, TN), Assem; Mahfoud (Memphis, TN)
Assignee:	St. Jude Children\'s Research Hospital (Memphis, TN)
Application Number:	09/974,619
Patent Claims:	1. A method for predicting CYP3A5 expression level in a subject comprising determining the nucleotide present in each CYP3A5 allele of the genomic DNA of said subject at the location(s) selected from the group consisting of: (a) the position corresponding to nucleotide 23 of SEQ ID NO:73 within intron 3 of the Cyp3A5 gene: (b) the position corresponding to nucleotide 29 of SEQ ID NO:74 within exon 7 of the Cyp3A5 gene; and (c) the positions corresponding to both nucleotide 23 of SEQ ID NO:73 and nucleotide 29 of SEQ ID NO:74; wherein the presence of an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 on at least one CYP3A5 allele of said subject predicts a relatively high level of expression of CYP3A5 as compared to the presence of a G at that position and the presence of a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 on each CYP3A5 allele of said subject predicts a relatively low level of expression of CYP3A5 as compared to the presence of an A at that position; wherein the presence of a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject predicts a relatively high level of expression of CYP3A5 as compared to the presence of an A at that position and the presence of an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject predicts a relatively low level of expression of CYP3A5 as compared to the presence of a G at that position; and wherein the presence of an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 and a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject predicts a relatively high level of expression of CYP3A5 as compared to the presence of a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 and an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject and the presence of either a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 or an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject predicts a relatively low level of expression of CYP3A5 as compared to the presence of either an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 or a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject. 2. The method of claim 1 wherein said location is the position corresponding to nucleotide 23 of SEQ ID NO:73 within intron 3 of the Cyp3A5 gene. 3. The method of claim 1 wherein said location is the position corresponding to nucleotide 29 of SEQ ID NO:74 within exon 7 of the Cyp3A5 gene. 4. The method of claim 1 wherein said locations are the positions corresponding to both nucleotide 23 of SEQ ID NO:73 and nucleotide 29 of SEQ ID NO:74. 5. The method of claim 1, 2, 3 or 4 wherein the step of determining the nucleotide present in each CYP3A5 allele of said subject at the selected location(s) is accomplished by sequencing a region of the genomic DNA of said subject which includes said location(s). 6. The method of claim 1, 2, 3 or 4 wherein the step of determining the nucleotide present in each Cyp3A5 allele of said subject at the selected location(s) is accomplished by (a) amplifying a region of the genomic DNA of said subject which includes said location(s) to generate an amplified fragment, and (b) treating the amplified fragment with a restriction enzyme in its corresponding restriction buffer to determine the identity of the nucleotide present at the selected location(s). 7. The method of claim 1, 2, 3 or 4 wherein the step of determining the nucleotide present in each Cyp3A5 allele of said subject at the selected location(s) is accomplished by (a) amplifying a region of the genomic DNA of said subject which includes said location(s), and (b) hybridizing the amplified region with probes specific for the selected location(s) wherein hybridization determines the identity of the nucleotide present at the selected location(s). 8. A method for determining the cytochrome P450 3A5 (CYP3A5) genotype and phenotype of an individual comprising: (a) isolating nucleic acid from the individual; (b) amplifying a region of the cytochrome P450 3A5 (CYP3A5) gene sequence selected from the group of: (i) intron 3 comprising the position corresponding to nucleotide 23 of SEQ ID NO:73; (ii) exon 7 comprising the position corresponding to nucleotide 29 of SEQ ID NO:74; and (iii) intron 3 comprising the position corresponding to nucleotide of SEQ ID NO:73 and exon 7 comprising the position corresponding to nucleotide 29 of SEQ ID NO:74; and (c) sequencing the amplified region of step (b), thereby determining the cytochrome P450 3A5 (CYP3A5) genotype and phenotype of the individual, wherein the cytochrome P450 3A5 phenotype is as follows: wherein the presence of an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 on at least one CYP3A5 allele of said subject is indicative of a relatively high level of expression of CYP3A5 as compared to the presence of a G at that position; or the presence of a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 on each CYP3A5 allele of said subject is indicative of a relatively low level of expression of CYP3A5 as compared to the presence of an A at that position; or wherein the presence of a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject is indicative of a relatively high level of expression of CYP3A5 as compared to the presence of an A at that position; or the presence of an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject is indicative of a relatively low level of expression of CYP3A5 as compared to the presence of a G at that position; or wherein the presence of an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 and a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject is indicative of a relatively high level of expression of CYP3A5 as compared to the presence of a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 and an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on at least one CYP3A5 allele of said subject; or the presence of either a G at the position corresponding to nucleotide 23 of SEQ ID NO:73 or an A at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject is indicative of a relatively low level of expression of CYP3A5 as compared to the presence of either an A at the position corresponding to nucleotide 23 of SEQ ID NO:73 or a G at the position corresponding to nucleotide 29 of SEQ ID NO:74 on each CYP3A5 allele of said subject. 9. The method of claim 8 wherein the intron 3 region of cytochrome P450 3A5 (CYP3A5) is amplified utilizing primers which amplify 5' and 3' of the position corresponding to nucleotide 23 of SEQ ID NO:73. 10. The method of claim 9 wherein the intron 3 region is amplified utilizing a set of primers, wherein said set of primers contains primer X and primer Y; wherein i) primer X has the sequence of SEQ ID NO: 24, or a fragment thereof which is at least ten nucleotides long; and primer Y has the sequence of SEQ ID NO: 25, or a fragment thereof which is at least ten nucleotides long; or ii) primer X has the sequence of SEQ ID NO: 26, or a fragment thereof which is at least ten nucleotides long, and primer Y has the sequence of SEQ ID NO: 27, or a fragment thereof which is at least ten nucleotides long. 11. The method of claim 8 wherein the exon 7 region of cytochrome P450 3A5 (CYP3A5) is amplified utilizing primers which amplify 5' and 3' of the position corresponding to nucleotide 29 of SEQ ID NO:74. 12. The method of claim 11 wherein the exon 7 region is amplified utilizing a set of primers, wherein said set of primers contains primer X and primer Y; wherein i) primer X has the sequence of SEQ ID NO: 30, or a fragment thereof which is at least ten nucleotides long; and primer Y has the sequence of SEQ ID NO: 16, or a fragment thereof which is at least ten nucleotides long; or ii) primer X has the sequence of SEQ ID NO: 31, or a fragment thereof which is at least ten nucleotides long, and primer Y has the sequence of SEQ ID NO: 32, or a fragment thereof which is at least ten nucleotides long. 13. A method of determining cytochrome P450 3A5 (CYP3A5) genotype of a subject which comprises (a) isolating nucleic acid from said subject; (b) amplifying a cytochrome P450 3A5 (CYP3A5) PCR fragment from said nucleic acid using a set of primers, wherein said set of primers contains primer X and primer Y; wherein i) primer X has the sequence of SEQ ID NO: 30, or a fragment thereof which is at least ten nucleotides long; and primer Y has the sequence of SEQ ID NO: 16, or a fragment thereof which is at least ten nucleotides long; or ii) primer X has the sequence of SEQ ID NO: 31, or a fragment thereof which is at least ten nucleotides long, and primer Y has the sequence of SEQ ID NO: 32, or a fragment thereof which is at least ten nucleotides long; and the amplified cytochrome P450 3A5 (CYP3A5) PCR fragment is in between primers X and Y; and (c) sequencing the amplified fragment obtained in step (b), thereby determining the cytochrome P450 3A5 (CYP3A5) exon 7 genotype of said subject. 14. A method for determining cytochrome P450 3A5 (CYP3A5) genotype of a subject which comprises: (a) isolating nucleic acid from said subject; (b) making a first and a second PCR primer wherein (i) the first PCR primer is complementary to exon 7 and introduces a base change in the PCR product produced by amplification with the first and second primer adjacent to or near the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7, such that a restriction site is generated in the presence of a particular nucleotide at the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7; and (ii) the second PCR primer is complementary to a region 3' to the exon 7 nucleotide in the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7; (c) amplifying the sequence in between the first and the second primers; thereby obtaining an amplified fragment; and (d) treating the amplified fragment obtained in step (c) with a restriction enzyme in its corresponding restriction buffer to detect presence or absence of a point mutation at the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7, thereby determining the cytochrome P450 3A5 (CYP3A5) genotype of said subject. 15. The method of claim 14 wherein the first primer introduces a Tru9I/MseI restriction site in the presence of an A nucleotide at the position corresponding to nucleotide 29 of SEQ NO:74 in exon 7, and the second primer has the sequence selected from SEQ ID NO:32 and SEQ ID NO:16, or a fragment thereof which is at least ten nucleotides long. 16. The method of claim 14 wherein the first primer has the sequence of SEQ ID NO: 34, or a fragment thereof which is at least ten nucleotides long, and the second primer has the sequence of SEQ ID NO: 32, or a fragment thereof which is at least ten nucleotides long. 17. The method of claim 14 wherein the first primer has the sequence of SEQ ID NO:34, or a fragment thereof which is at least ten nucleotides long, and the second primer has the sequence of SEQ ID NO:16, or a fragment thereof which is at least ten nucleotides long. 18. A method for determining cytochrome P450 3A5 (CYP3A5) exon 7 genotype of a subject which comprises: (a) isolating nucleic acid from said subject; (b) amplifying a cytochrome P450 3A5 (CYP3A5) PCR fragment from said nucleic acid using a first set of primers, wherein said first set of primers contains primer X and primer Y; wherein (i) the X primer is complementary to a region 5' to the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7; and (ii) the Y primer is complementary to a region 3' to the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7; and the amplified cytochrome P450 3A5 (CYP3A5) PCR fragment is in between primers X and Y, thereby obtaining a first round amplified fragment; (c) amplifying the first round amplified fragment of step (b) using a second set of primers, wherein said second set of primers contains primer Z and primer W, wherein (i) primer Z is complementary to exon 7 and introduces a base change in the PCR product produced by amplification with the second set of primers adjacent to or near the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7, such that a restriction site is generated in the presence of a particular mutation at the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7; and (ii) primer W is complementary to a region 3' to exon 7; and the amplified sequence is in between primers Z and W; and (d) treating the amplified fragment obtained in step (c) with a restriction enzyme in its corresponding restriction buffer to detect presence or absence of a point mutation at the position corresponding to nucleotide 29 of SEQ ID NO:74 in exon 7, thereby determining the cytochrome P450 3A5 (CYP3A5) genotype of said subject. 19. The method of claim 18 wherein primer X has the sequence of SEQ ID NO:30, or a fragment thereof which is at least ten nucleotides long; primer Y has the sequence of SEQ ID NO: 16, or a fragment thereof which is at least ten nucleotides long; primer Z introduces a Tru9I/MseI restriction site in the presence of an A nucleotide at the position corresponding to nucleotide 29 of SEQ ID NO: 74 in exon 7; and primer W has the sequence selected from SEQ ID NO:32 and SEQ ID NO:16, or a fragment thereof which is at least ten nucleotides long. 20. The method of claim 19 wherein primer Z has the sequence of SEQ ID NO: 34, or a fragment thereof which is at least ten nucleotides long.

Details for Patent 7,022,475

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26